2. UroToday Home
  3. Center Of Excellence
  4. Advanced Prostate Cancer
  5. From The Editor
Back to Advanced Prostate Cancer    

Welcome Letter from the Advanced Prostate Cancer Center of Excellence Editor

For more than 20 years, UroToday has been THE premier online educational resource for genitourinary oncology – clinicians educating clinicians. During this time, advanced prostate cancer has been completely transformed, pa≥ particularly in the last 10+ years. Since then, we have seen (briefly) the following in advanced prostate cancer:

  • Docetaxel for mCRPC progression
  • Cabazitaxel following docetaxel for mCRPC progression
  • Radium-223 for mCRPC
  • Docetaxel + ADT for mHSPC
  • Abiraterone + prednisone for mHSPC
  • ARPIs + ADT for mHSPC
  • ARPIs + ADT for M0 CRPC
  • Enzalutamide +/- ADT for non-metastatic HSPC
  • PARP inhibitors for mCRPC
  • Radioligand therapy for mCRPC
Throughout this time, UroToday has been at the forefront of educating and ensuring clinicians are up to date with the latest prostate cancer information and data. Indeed, with each major oncology meeting it seems that the advanced prostate cancer landscape is changing. Not only does UroToday provide ‘straight to your inbox’ conference coverage, this Center of Excellence collates all of the discussions with global prostate cancer experts, guidelines updates, journal club discussions, and much more.

While the last decade has been exciting, we have much work to do. Globally, more than half of men do not receive treatment intensification for mHSPC, the majority of men do not receive genomic/somatic genetic testing, and patients fail our latest and greatest treatment regimens. While these reasons are no doubt multifactorial, we must continue recruiting to clinical trials and educating clinicians who cannot attend global oncology meetings and who may not have access to expensive medical journals.

Since 2016 as a Society of Urologic Oncology fellow I have had the privilege of contributing to the UroToday platform. I am humbled and excited to be named the new editor of the Advanced Prostate Cancer Center of Excellence. I am passionate about prostate cancer and UroToday. As we have for more than 20 years, we will continue to be the “go to” online resource for staying contemporary in the advanced prostate cancer disease space. This is a team effort – an advanced ‘thank you’ to our global community of experts who will contribute their time and expertise for education, and to you the clinician – eager to learn and improve treatment options and delivery of care for our advanced prostate cancer patients.

Yours,

Zachary Klaassen, MD, MSc, Urologist Oncologist, Associate Professor of Urology, Georgia Cancer Center; Wellstar MCG Health, Augusta, GA